Point72 Hong Kong’s Avita Medical RCEL Stock Holding History

Point72 Hong Kong’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-145	Closed	-$1K	–	2337
2022 Q2	$1K	Buy	+145	New	+$896	﹤0.01%	1822

Other funds holding RCEL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Point72 Hong Kong's RCEL Position: Q3 2022 in Review

Point72 Hong Kong sold out of Avita Medical (RCEL) in Q3 2022, closing a stake of 145 shares — an estimated $1K sold.

Point72 Hong Kong first reported a position in RCEL in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 48 funds tracked by Wall St. Rank hold RCEL as of Q3 2022.

Point72 Hong Kong reported no remaining Avita Medical position as of Q3 2022 after selling out during the quarter.
Point72 Hong Kong sold 145 Avita Medical shares in Q3 2022, an estimated $1K.
Point72 Hong Kong first reported a position in Avita Medical in Q2 2022 and held it in 1 quarter.
Point72 Hong Kong's Avita Medical position peaked at $1K in Q2 2022.
48 funds tracked by Wall St. Rank held Avita Medical as of Q3 2022.

Based on Point72 Hong Kong's 13F filing for Q3 2022, filed 14 Nov 2022.